NCT01012739 - Efficacy, Safety, Tolerability, and Pharmacokinetics of Indacaterol Maleate Via Concept1 or Simoon Devices | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2009

Primary Completion Date

March 31, 2010

Study Completion Date

March 31, 2010

Conditions

Asthma

Interventions

DRUG

Indacaterol 150 μg via the Concept1 dry-powder inhaler

Indacaterol maleate 150 μg was provided in powder filled capsules with the Concept1 dry-powder inhaler.

DRUG

Indacaterol 60 μg via the Simoon dry-powder inhaler

Indacaterol 60 μg was provided in powder filled capsules with the Simoon dry-powder inhaler.

DRUG

Indacaterol 120 μg via the Simoon dry-powder inhaler

Indacaterol 120 μg was provided in powder filled capsules with the Simoon dry-powder inhaler.

DRUG

Placebo to indacaterol via the Concept1 dry-powder inhaler

Placebo to indacaterol was provided in powder filled capsules with the Concept1 dry-powder inhaler.

Trial Locations (4)

Novartis Investigative Site, Berlin

Novartis Investigative Site, Groningen

Novartis Investigative Site, Belfast

Novartis Investigative Site, Manchester